When an elderly patient presents with a severe, relentless itch, it is easy to assume it is just dry skin or standard eczema. However, at the Rapids 2026 conference in Fort Lauderdale, a masterclass lecture by Dr. Issa shook up that clinical complacency.
In a sit-down interview with host dermatology PA Eileen Cheever, Dr. Issa broke down the nuances, diagnostic pitfalls, and cutting-edge treatments for the two heavy hitters of autoimmune blistering: Bullous Pemphigoid (BP) and Pemphigus Vulgaris (PV).
Here is what every dermatology clinician needs to know to keep these life-altering conditions high on their differential.
The classic textbook image of Bullous Pemphigoid is a patient covered in large, tense, fluid-filled blisters (bullae). But Dr. Issa warns that waiting for the blisters to appear means you are catching the disease late.
BP is a clinical continuum that frequently morphs over time:
Clinical Pearl: Always perform a meticulous medication review. Drug-induced bullous pemphigoid is incredibly common. If you don't rule out an inciting drug, you cannot fully resolve the disease.
If you suspect BP, your biopsy technique must be highly strategic. Dr. Issa mapped out exactly where your blades should go:
| Suspected Disease | Biopsy Type | Exact Anatomical Location | Clinical Rationale |
| Bullous Pemphigoid (BP) |
H&E (Histology) |
Lesional edge of a tense blister. | Captures the intact epidermal-dermal split; placing the punch directly in the center of the bulla can tear the epidermis off, leaving an unreadable sample. |
| Bullous Pemphigoid (BP) |
DIF (Direct Immunofluorescence) |
Perilesional skin (normal-appearing skin within 1 cm of the lesion). | Autoantibodies (IgG, IgA, IgM) pool along the basement membrane zone here before the tissue formally splits into a blister. |
| Pemphigus Vulgaris (PV) |
H&E (Histology) |
Lesional edge of a flaccid blister or erosion. | Reveals the superficial, intraepidermal blistering and acantholysis (loss of keratinocyte adhesion) higher up in the stratum corneum. |
| Pemphigus Vulgaris (PV) |
DIF (Direct Immunofluorescence) |
Perilesional skin or unaffected mucosa. | Captures the classic "chicken wire" pattern in which antibodies coat the cell surfaces of keratinocytes. |
Serologically, checking for BP-180 and BP-230 antibodies helps track disease activity, as these levels wax and wane with inflammatory activity.
Excitingly, our understanding of BP's pathophysiology has shifted toward Type 2 inflammation. Interleukins 4 and 13 (IL-4 and IL-13) bind to receptors on B cells, signaling them to churn out the destructive autoantibodies. Because of this direct pathway, dupilumab has emerged as a targeted, FDA-approved breakthrough to stop this cascade without globally suppressing the immune system of elderly patients.
While BP occurs deep at the dermal-epidermal junction, Pemphigus Vulgaris attacks further up in the epidermis, targeting the Desmoglein (DSG-1 and DSG-3) adhesion proteins that act as the structural "brick and mortar" holding keratinocytes together.
Because PV compromises structural bonds higher up in the skin, the blisters are flaccid, fragile, and easily ruptured. On a diagnostic workup:
Unlike many outpatient dermatology conditions, severe Pemphigus Vulgaris can rapidly escalate into a medical emergency. Dr. Issa highlighted the critical complications that require immediate ER referral or multi-specialty intervention:
When conceptualizing treatment for these autoimmune blistering disorders, the goal is simple: stop the production of autoantibodies.
| Drug Class / Therapy | Mechanism of Action | Clinical Application |
| Rituximab | Anti-CD20 monoclonal antibody that destroys the B-cell source. | Current Standard of Care for Pemphigus Vulgaris. |
| Dupilumab | Blocks IL-4 and IL-13 signaling to halt autoantibody generation. | FDA-Approved and highly effective for Bullous Pemphigoid. |
| JAK Inhibitors | Block downstream JAK-STAT signaling to prevent keratinocyte destruction. | Emerging Frontier (Recent data shows topical JAK-1/JAK-2 inhibition can resolve PV lesions). |
| Systemic Corticosteroids | Broad, immediate immunosuppression. | Used to quickly slam the immune system during acute flares. |
Autoimmune blistering diseases require a sharp eye, careful biopsy placement, and rapid intervention. By keeping BP on your radar for every itchy elderly patient and treating widespread PV with the urgency of a burn injury, you can drastically alter your patient's disease trajectory.
Listen to the entire podcast on Apple Podcasts or Spotify